Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

effective at 5:00 p.m. EDT on Tuesday, August 20, 2013.

Stockholders holding shares in "street name" through a brokerage account will have their shares automatically adjusted to reflect the reverse stock split and change in name.  

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.  The Company's product Ceplene®, when used concomitantly with low-dose IL-2 is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission.  The Company sold all of its rights to Ceplene® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene® inventory to Meda AB in June 2012.  The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.  In November 2012, EpiCept and Immune Pharmaceuticals Ltd., a privately held Israeli company, entered into a definitive merger agreement.  The transaction is anticipated to close this week.  The combined company will be focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.

About Immune Pharmaceuticals Ltd.

Immune Pharmaceuticals Ltd. is an Israel and U.S.-based biopharmaceutical company focused on the development of next-generation antibody therapeutics to address unmet medical needs in the treatment of inflammatory diseases and cancer. Im
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 Research and Markets has ... Proteomics Analytical Instruments Market 2014-2018" report to their ... Genomics is the study of the gene and ... structure and functions of proteomes or sets of proteins ... Genomics involves the mapping of genes and DNA sequencing ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... Brad Thompson, President,and CEO of Oncolytics Biotech Inc. (TSX: ... Company at the Maxim Group Growth Conference at,2:30 p.m. ... being held at the,Grand Hyatt Hotel in New York., ... is available at, http://www.wsw.com/webcast/maxim/oncy/ on the company,s website ...
... Engineering and Operations Appointed -, CLINTON, N.J., ... appointment of Michael Kennedy as Senior Vice President,Engineering ... responsible for,drug-device technology strategy and development., "Michael,s ... critical care as we continue to advance our ...
... Oct. 2 ,ImpediMed Ltd, a pioneer in ... Inc., a global leader in science-based,nutraceutical products, ... announced an agreement to distribute ImpediMed technology,in ... affiliate, Health,World, Ltd, has been a long-standing ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference 2Ikaria Strengthens Executive Leadership Team 2ImpediMed and Metagenics Announce Agreement 2
(Date:7/24/2014)... TORONTO, June 24, 2014 Some sticky research out ... fight against a certain species of toxic grass fungus: ... this month,s Biology Letters , "Ungulate saliva inhibits ... when applied to red fescue grass (which hosts a ... results in slower fungus growth and less toxicity. , ...
(Date:7/24/2014)... Iyer, O.D., a low vision specialist at The University ... School, has been awarded a grant to help Harris ... eyeglasses, medication or surgery. , Even with corrective lenses, ... best. However, there are a variety of low vision ... help offset their vision loss. , Iyer is using ...
(Date:7/24/2014)... fire hazard in the United States, wildland managers often ... and suppressed trees (ladder fuels). These cuttings and ... low fire danger in order to dispose of the ... pollutants, managers often cover all or part of the ... as agricultural plastic, in order to keep water out. ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... and a half acres of Appalachia have been strip-mined, whole ... and communities devastated. Not exactly a promising place for a ... For his startling and bold proposal to clean-up this ... of Appalachia, John Todd, a research professor in the Rubenstein ...
... drug reverses the brain dysfunction inflicted by a genetic ... of TSC patients also suffer from autism, the findings ... autism. Nature Medicine publishes the findings ... mouse model for TSC, the scientists tested rapamycin, a ...
... the Smithsonian,s National Zoo detected a secondary rise in ... Mei Xiang (may-SHONG) earlier this month. The results from ... believe the hormone rise indicates that it would be ... to a cub or comes to the end of ...
Cached Biology News:Buckminster Fuller takes on big coal 2Buckminster Fuller takes on big coal 3Drug reverses mental retardation caused by genetic disorder 2
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: